C Jorgensen

Summary

Country: France

Publications

  1. ncbi Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis
    F Apparailly
    INSERM U475, Montpellier, France
    Arthritis Rheum 44:1444-54. 2001
  2. ncbi Tissue engineering through autologous mesenchymal stem cells
    Christian Jorgensen
    Service d Immuno Rhumatologie, Hopital Lapeyronie, 34295 Montpellier, Cedex 5, France
    Curr Opin Biotechnol 15:406-10. 2004
  3. pmc Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis
    J Sany
    Service d Immuno Rhumatologie, Hopital Lapeyronie, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
    Ann Rheum Dis 64:1647-9. 2005
  4. ncbi Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells
    Bruno Delorme
    INSERM, Equipe ESPRI EA 3855, Faculty of Medicine, University Francois Rabelais, 10 boulevard Tonnelle, Tours, France
    Blood 111:2631-5. 2008
  5. pmc Microenvironmental changes during differentiation of mesenchymal stem cells towards chondrocytes
    Farida Djouad
    INSERM, U 844, 80 avenue Augustin Fliche, Montpellier, F 34091 France
    Arthritis Res Ther 9:R33. 2007
  6. pmc Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005
    Alan Tyndall
    Rheumatology, University Hospital Basel, Felix Platter Spital, Burgfelderstrasse 101, Basel, CH 4012, Switzerland
    Arthritis Res Ther 9:301. 2007
  7. pmc Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells
    Farida Djouad
    INSERM Unit 475, Montpellier, France
    Arthritis Res Ther 7:R1304-15. 2005
  8. pmc Could inflammatory arthritis be triggered by progenitor cells in the joints?
    C Jorgensen
    Immuno Rheumatology Department, INSERM U475, 34295 Montpellier, France
    Ann Rheum Dis 61:6-9. 2002
  9. doi Multipotent mesenchymal stromal cells in articular diseases
    Christian Jorgensen
    INSERM U844, CHU Saint Eloi, bâtiment INM, 80 avenue Augustin Fliche, Montpellier F 34091, France
    Best Pract Res Clin Rheumatol 22:269-84. 2008
  10. doi Cytosolic phospholipase A2α gene silencing in the myeloid lineage alters development of Th1 responses and reduces disease severity in collagen-induced arthritis
    G Courties
    Inserm U 844, Hopital Saint Eloi, and Université Montpellier I, Montpellier, France
    Arthritis Rheum 63:681-90. 2011

Collaborators

Detail Information

Publications50

  1. ncbi Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis
    F Apparailly
    INSERM U475, Montpellier, France
    Arthritis Rheum 44:1444-54. 2001
    ....
  2. ncbi Tissue engineering through autologous mesenchymal stem cells
    Christian Jorgensen
    Service d Immuno Rhumatologie, Hopital Lapeyronie, 34295 Montpellier, Cedex 5, France
    Curr Opin Biotechnol 15:406-10. 2004
    ..The long-term behavior of MSCs associated with biomaterials and implanted in pathological joints remains to be investigated before clinical application in osteoarthritis or rheumatoid arthritis...
  3. pmc Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis
    J Sany
    Service d Immuno Rhumatologie, Hopital Lapeyronie, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
    Ann Rheum Dis 64:1647-9. 2005
    ..To determine whether patients with an atopic diathesis had a better response to corticosteroid pretreatment than those without, and the course of patients' functional capacity and quality of life...
  4. ncbi Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells
    Bruno Delorme
    INSERM, Equipe ESPRI EA 3855, Faculty of Medicine, University Francois Rabelais, 10 boulevard Tonnelle, Tours, France
    Blood 111:2631-5. 2008
    ..In addition, the expression of CD73, CD146, and CD200 was down-regulated in differentiated cells. The new marker CD200, because of its specificity and immunomodulatory properties, deserves further in-depth studies...
  5. pmc Microenvironmental changes during differentiation of mesenchymal stem cells towards chondrocytes
    Farida Djouad
    INSERM, U 844, 80 avenue Augustin Fliche, Montpellier, F 34091 France
    Arthritis Res Ther 9:R33. 2007
    ..Our data suggest that crosstalk between ECM components of the microenvironment and MSCs within the cartilage is responsible for the differentiation of MSCs into chondrocytes...
  6. pmc Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005
    Alan Tyndall
    Rheumatology, University Hospital Basel, Felix Platter Spital, Burgfelderstrasse 101, Basel, CH 4012, Switzerland
    Arthritis Res Ther 9:301. 2007
    ..This review summarizes the findings of a 1-day meeting devoted to the subject with the aim of coordinating efforts...
  7. pmc Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells
    Farida Djouad
    INSERM Unit 475, Montpellier, France
    Arthritis Res Ther 7:R1304-15. 2005
    ....
  8. pmc Could inflammatory arthritis be triggered by progenitor cells in the joints?
    C Jorgensen
    Immuno Rheumatology Department, INSERM U475, 34295 Montpellier, France
    Ann Rheum Dis 61:6-9. 2002
  9. doi Multipotent mesenchymal stromal cells in articular diseases
    Christian Jorgensen
    INSERM U844, CHU Saint Eloi, bâtiment INM, 80 avenue Augustin Fliche, Montpellier F 34091, France
    Best Pract Res Clin Rheumatol 22:269-84. 2008
    ..This chapter focuses on the potential of MSC to repair cartilage, with an emphasis on the factors that are known to be required in inducing chondrogenesis and on their immunosuppressive potential...
  10. doi Cytosolic phospholipase A2α gene silencing in the myeloid lineage alters development of Th1 responses and reduces disease severity in collagen-induced arthritis
    G Courties
    Inserm U 844, Hopital Saint Eloi, and Université Montpellier I, Montpellier, France
    Arthritis Rheum 63:681-90. 2011
    ....
  11. ncbi Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis
    F Apparailly
    Unité de Recherches d Immunopathologie des Maladies Tumorales et Autoimmunes, Institut National de la Santé et de la Recherche Médicale U475, Montpellier, France
    J Immunol 160:5213-20. 1998
    ..Our data indicate that a single systemic administration of an adenoviral vector encoding vIL-10 may be a good candidate to suppress arthritis...
  12. ncbi Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis
    F Apparailly
    INSERM U475, Montpellier, France
    Gene Ther 9:192-200. 2002
    ..The preventive effect observed on arthritis was related to the decrease in angiogenesis, rather than inhibition of extracellular matrix degradation...
  13. ncbi Longitudinal determination of antiphospholipid antibodies in lupus patients without previous manifestations of antiphospholipid syndrome. A prospective study
    M De Bandt
    Rheumatology Unit, Bichat Teaching Hospital, Paris, France
    J Rheumatol 26:91-6. 1999
    ..To investigate whether serial anticardiolipin determination contributes to the clinical management of patients with systemic lupus erythematosus (SLE) with no previous sign of the antiphospholipid syndrome (APS)...
  14. doi miRNAs and rheumatoid arthritis - promising novel biomarkers
    Isabelle Duroux-Richard
    INSERM U844, CHU Saint Eloi, bâtiment INM, 80 rue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Swiss Med Wkly 141:w13175. 2011
    ..As a growing body of evidences reveals abnormal expression of specific miRNAs in RA tissues, the use of a blood-based miRNA signature for optimal diagnosis and treatment becomes a realistic option...
  15. doi Bone-metastatic prostate carcinoma favors mesenchymal stem cell differentiation toward osteoblasts and reduces their osteoclastogenic potential
    V Fritz
    INSERM U844, Hopital Saint Eloi, Montpellier, F 34295, France
    J Cell Biochem 112:3234-45. 2011
    ..Altogether, these findings allow us to propose clues to understand the mechanisms by which PC favors bone synthesis by regulating MSC outcome and properties...
  16. ncbi [Gene transfer immunotherapy in rheumatoid arthritis: perspectives]
    C Jorgensen
    Service d'immunorhumatologie, , 34295 Montpellier, France
    Rev Med Interne 22:163-71. 2001
    ..The previous clinical data on gene therapy in rheumatoid arthritis are limited to feasibility studies. We believe that the efficiency of gene therapy will be obtained by combining two or more complementary targets...
  17. doi The role of miR-155 in regulatory T cells and rheumatoid arthritis
    D Spoerl
    INSERM U844, CHU Saint Eloi, INM, 80 rue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Clin Immunol 148:56-65. 2013
    ..In a final perspective section we discuss the potential impact of therapeutic miR-155 modulation in RA...
  18. ncbi Adeno-associated virus pseudotype 5 vector improves gene transfer in arthritic joints
    F Apparailly
    INSERM U475, and Université Montpellier I, 34197 Montpellier, France
    Hum Gene Ther 16:426-34. 2005
    ..These findings provide a practical application for future local AAV-mediated gene therapy trials in RA...
  19. ncbi Feline immunodeficiency virus vectors for efficient transduction of primary human synoviocytes: application to an original model of rheumatoid arthritis
    Yea Lih Lin
    Institut de Genetique Humaine, CNRS UPR1142, 34396 Montpellier Cedex 5, France
    Hum Gene Ther 15:588-96. 2004
    ..FIV vectors appear to be promising tools for biologic research and gene therapy...
  20. ncbi Multipotent mesenchymal stromal cells and immune tolerance
    Daniele Noel
    Universite Montpellier 1, Montpellier, France
    Leuk Lymphoma 48:1283-9. 2007
    ..Finally, the data obtained from in vivo experimentation in various animal models as well as potential therapeutic applications will be presented...
  21. ncbi Immunomodulatory dendritic cells inhibit Th1 responses and arthritis via different mechanisms
    Leonie M van Duivenvoorde
    Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
    J Immunol 179:1506-15. 2007
    ..These data indicate that distinct mechanisms can be used by distinct DC subsets to change the outcome of autoimmunity...
  22. ncbi RNAi in arthritis: prospects of a future antisense therapy in inflammation
    Maroun Khoury
    Inserm U 844, INM Hôpital Saint Eloi, BP 74103, 80 rue Augustin Fliche, 34091 Montpellier Cedex 5, France
    Curr Opin Mol Ther 9:483-9. 2007
    ..In addition, RNAi and current biotherapies used in the clinic are compared and contrasted...
  23. ncbi Tetracycline transcriptional silencer tightly controls transgene expression after in vivo intramuscular electrotransfer: application to interleukin 10 therapy in experimental arthritis
    Norma Perez
    Genethon, CNRS URA 1923, 91000 Evry, France
    Hum Gene Ther 13:2161-72. 2002
    ..We conclude that the use of tTS significantly improves the utility of the rtTA system for somatic gene transfer by reducing background activity...
  24. ncbi Mesenchymal stem cells: an emerging tool for cancer targeting and therapy
    Vanessa Fritz
    INSERM U844, CHU Hôpital Saint Eloi Bâtiment INM, BP74103, 80 rue Augustin Fliche, 34091 Montpellier Cedex 5, France
    Curr Stem Cell Res Ther 3:32-42. 2008
    ..This review highlights recent works and potential clinical applications of MSCs in this field...
  25. doi Transient down-regulation of cbfa1/Runx2 by RNA interference in murine C3H10T1/2 mesenchymal stromal cells delays in vitro and in vivo osteogenesis, but does not overtly affect chondrogenesis
    Jan O Gordeladze
    Institute of Basal Medical Sciences, Department of Biochemistry, University of Oslo, Norway
    Exp Cell Res 314:1495-506. 2008
    ..These experiments indicate that a major transient reduction of cbfa1/Runx2 expression in MSCs is sufficient to delay osteoblastic differentiation, both in vitro and in vivo, while chondrogenesis seemed to be sustained...
  26. doi Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials
    Daniele Noel
    INSERM U844, Montpellier, F 34091 France
    Exp Cell Res 314:1575-84. 2008
    ..In summary, our observations indicate that ADSC and MSC are fundamentally different cell types and differently committed cells...
  27. pmc Concise review: adult multipotent stromal cells and cancer: risk or benefit?
    Gwendal Lazennec
    Institut National de la Sante et de la Recherche Medicale, Montpellier, France
    Stem Cells 26:1387-94. 2008
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  28. doi [Multipotent stromal cells: controversial impact on tumor development and metastasis]
    Florence Apparailly
    INSERM, U844, INM, Hopital Saint Eloi, 80 rue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Med Sci (Paris) 24:359-60. 2008
  29. ncbi Immature dendritic cells suppress collagen-induced arthritis by in vivo expansion of CD49b+ regulatory T cells
    Louis Marie Charbonnier
    Institut National de la Santé et de la Recherche Médicale Unité 475, Montpellier, France
    J Immunol 177:3806-13. 2006
    ..Thus, together these data demonstrate that iDCs can expand and activate a novel regulatory population of CD49b+ T cells, with high immunosuppressive potential able to mediate protection against a systemic autoimmune disease...
  30. doi Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes
    Maroun Khoury
    INSERM, U 844, INM, Hopital St Eloi, and Université Montpellier 1, UFR de Medecine, Montpellier, France
    Arthritis Rheum 58:2356-67. 2008
    ..As proof of concept, we tested the efficiency of an RNA interference (RNAi)-based intervention that targets proinflammatory cytokines in suppressing murine collagen-induced arthritis (CIA)...
  31. ncbi Gene therapy for rheumatoid arthritis
    Natacha Bessis
    UPRES EA 3408 Université Paris 13 and Service de Rhumatologie CHU Avicenne, AP HP, Bobigny, France
    J Gene Med 4:581-91. 2002
    ..The best target remains to be determined and extensive research has to be conducted in preclinical studies...
  32. ncbi Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis
    Florence Apparailly
    Unité de Recherche en Immunopathologie des Maladies Tumorales et Autoimmunes, INSERM U475, France
    Hum Gene Ther 13:1179-88. 2002
    ..Our results supported, for the first time, the utility of AAV-tetON-vIL10 as a therapeutic tool for gene therapy in RA...
  33. ncbi Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism
    Farida Djouad
    Institut National de la Sante et de la Recherche Medicale, U 844, Hopital Saint Eloi, Bât INM, 80 avenue Augustin Fliche, Montpellier, France
    Stem Cells 25:2025-32. 2007
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  34. ncbi Engineered mesenchymal stem cells for cartilage repair
    Farida Djouad
    INSERM, U 475, 99 rue Puech Villa, 34197 Montpellier Cedex 5, France
    Regen Med 1:529-37. 2006
    ..Here, we focus on the potential of MSCs to repair cartilage with an emphasis on the factors that are known to be required in inducing chondrogenesis...
  35. ncbi Chondrogenic differentiation of murine and human mesenchymal stromal cells in a hyaluronic acid scaffold: differences in gene expression and cell morphology
    Gina Lisignoli
    Laboratorio di Immunologia e Genetica, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
    J Biomed Mater Res A 77:497-506. 2006
    ..These data demonstrate that C3H10T1/2 murine cells, widely used as a chondrogenic model, show a different sequence of chondrogenic events in hyaluronic acid scaffold, compared with primary h-MSCs...
  36. ncbi Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis
    Farida Djouad
    INSERM U475, Montpellier, France
    Arthritis Rheum 52:1595-603. 2005
    ..Using a murine model of rheumatoid arthritis (RA), this study investigated whether the immunosuppressive properties of MSCs could be of therapeutic value to inhibit reactive T cells in autoimmune diseases such as RA...
  37. ncbi Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system
    Yossi Gafni
    Skeletal Biotechnology Laboratory, Hebrew University Hadassah Medical Center, Ein Kerem, P O Box 12272, Jerusalem 91120, Israel
    Mol Ther 9:587-95. 2004
    ..Thus, the Tet-regulated rAAV-hBMP-2 vector is an effective means of induction and regulation of bone regeneration and repair...
  38. ncbi Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis
    Maroun Khoury
    INSERM U475 and University of Montpellier I, Montpellier, France
    Arthritis Rheum 54:1867-77. 2006
    ..The aim of this study was to determine the therapeutic effect of systemic administration of TNFalpha siRNA in an experimental model of RA, optimizing its delivery using new liposome formulations...
  39. ncbi Short-term BMP-2 expression is sufficient for in vivo osteochondral differentiation of mesenchymal stem cells
    Daniele Noel
    INSERM U475, Montpellier, France
    Stem Cells 22:74-85. 2004
    ....
  40. ncbi Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells
    Farida Djouad
    INSERM U475, Montpellier, France
    Transplantation 82:1060-6. 2006
    ..However, because of their immunosuppressive capacities, we investigated the effect of MSC on the development of syngeneic tumors...
  41. ncbi Micro-CT combined with bioluminescence imaging: a dynamic approach to detect early tumor-bone interaction in a tumor osteolysis murine model
    Vanessa Fritz
    INSERM U844, CHU Saint Eloi, 80 rue Augustin Fliche, 34091 Montpellier Cedex 5, France
    Bone 40:1032-40. 2007
    ..This model will help to assess new therapeutic approaches targeting intraosseous tumor growth or tumor/osteoclast crosstalk...
  42. ncbi Mesenchymal stem cells and rheumatoid arthritis
    Christian Jorgensen
    Immunorheumatology Department, Lapeyronie Hospital, 34295 Montpellier Cedex 5, France
    Joint Bone Spine 70:483-5. 2003
  43. ncbi Cell surface CCR5 density determines the intensity of T cell migration towards rheumatoid arthritis synoviocytes
    Caroline Desmetz
    Institut de Génétique Humaine du CNRS UPR1142, Montpellier, F 34000, France
    Clin Immunol 123:148-54. 2007
    ..The CCR5 density on T cell surface, which is constant over time for a given individual, but varies drastically from one individual to another, might thus be a factor determining the intensity of joint inflammation in the course of RA...
  44. ncbi Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
    Farida Djouad
    INSERM U475, 99 rue Puech Villa, 34197 Montpellier Cedex 5, France
    Blood 102:3837-44. 2003
    ..Although the potential side effects of immunosuppression induced by MSCs have to be considered in further clinical studies, the usefulness of MSCs for various therapeutic applications still remains of great interest...
  45. ncbi Antigen-specific immunomodulation of collagen-induced arthritis with tumor necrosis factor-stimulated dendritic cells
    Leonie M van Duivenvoorde
    Leiden University Medical Centre, Leiden, The Netherlands
    Arthritis Rheum 50:3354-64. 2004
    ..In this study, we explored the immunologic effects of differentially matured DCs on the development of collagen-induced arthritis (CIA)...
  46. ncbi CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis
    Ursula Mason
    GlaxoSmithKline Pharmaceuticals, Greenford, Middlesex, UK
    J Rheumatol 29:220-9. 2002
    ..Double blind studies were conducted with the anti-CD4 monoclonal antibody (Mab) keliximab in patients with active, stable rheumatoid arthritis (RA), to confirm preliminary evidence of efficacy and safety from open. uncontrolled studies...
  47. ncbi Leflunomide-induced aseptic meningitis
    Jean David Cohen
    Immuno Rheumatology Department, Hopital Lapeyronie, 34295 Montpellier Cedex 5, France
    Joint Bone Spine 71:243-5. 2004
    ..Drug-induced aseptic meningitis is uncommon and occurs primarily in patients with autoimmune disease. We report the first known case of leflunomide-induced aseptic meningitis, in a patient with rheumatoid arthritis...
  48. doi Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-kappaB pathway in breast cancer
    Carine Chavey
    Institut National de la Santé et de la Recherche Mé dicale, U844, University of Montpellier I, 34091 Montpellier Cedex 5, France
    Mol Pharmacol 74:1359-66. 2008
    ..TSA increased binding of acetylated histone 3 to the IL-8 gene promoter. In summary, our results demonstrate that NF-kappaB pathway repression by HDAC is responsible for the low expression of IL-8 in ERalpha-positive breast cancer cells...
  49. ncbi Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab
    Sylvie Fabre
    Department of Immuno Rheumatology, Centre Hospitalier Universitaire Lapeyronie, Montpellier, France
    J Rheumatol 32:2432-3. 2005
    ..We describe a patient receiving infliximab who developed a primary cutaneous Nocardia otitidiscaviarum infection after a skin injury...
  50. ncbi Tissue engineering through mesenchymal stem cells: role of the Genostem Consortium
    Christian Jorgensen
    Regen Med 1:493-6. 2006